Synovial sarcoma (SS) is a rare sarcoma driven by a translocation between SS18 and SSX
1, 2, or 4. With approximately 800 to 1,000 cases a year in the United States, it most …

Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50
subtypes. Historically, there have been few systemic treatment options for this relatively rare …

Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome-
and immune-targeted drugs that have transformed the outcomes of some malignancies …

Next-generation sequencing (NGS) can identify novel cancer targets. However, interpreting
the molecular findings and accessing drugs/clinical trials is challenging. Furthermore, many …

Background Malignancies are molecularly complex and become more resistant with each
line of therapy. We hypothesized that offering matched, individualized combination therapies …

Purpose Genomic profiling is increasingly used in the management of cancer. We have
previously reported preliminary results of our precision medicine program. Here, we present …

Carcinoma of unknown primary (CUP) is a rare and difficult-to-treat malignancy, the
management of which might be improved by the identification of actionable driver mutations …

Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment
of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small …

Purpose: Molecular profiling has been used to select patients for targeted therapy and
determine prognosis. Noninvasive strategies are critical to hepatocellular carcinoma (HCC) …

Lung cancer is the leading cause of cancer-related deaths worldwide. As the most prevalent
molecular mutation subtypes in non-small cell lung cancer (NSCLC), EGFR-TKIs are …